- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07900607
The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
This study looks at how the body handles an investigational drug called OD-001. Researchers want to learn how the medicine is absorbed, how it is broken down, and how it leaves the body.
About 8 healthy men will join the study, so that at least 6 people complete it. Each participant will drink a single dose of OD-001 as a liquid. This will be done on an empty stomach, so each participant will be asked not to eat for a period of time beforehand.
The medicine contains a small amount of a radioactive "tracer" (carbon-14). The tracer lets researchers follow the medicine and its breakdown products through your body. The amount of radioactivity is small and carefully limited. After the dose, researchers will collect samples such as blood, urine and stool. These will show how much of the medicine is recovered and what it turns into in the body.
Descripción general del estudio
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Kelly Bourdon
- Número de teléfono: 857-393-6160
- Correo electrónico: clinicaltrials@odysseytx.com
Ubicaciones de estudio
-
-
-
Ruddington, Reino Unido
- Reclutamiento
- Quotient Sciences
-
Contacto:
- Study Coordinator
- Número de teléfono: +44 (0)115 974 9000
- Correo electrónico: clinicaltrials@odysseytx.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged 30 to 65 years inclusive at the time of signing informed consent
- Must agree to adhere to the contraception requirements. In addition, vasectomised male participants with partners of childbearing potential must have received medical assessment of the surgical success of the procedure Healthy male participants according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs, single 12-lead ECGs, and laboratory safety tests without any clinically significant abnormalities as measured at screening. ECGs and vital signs to be re-checked at pre-dose.
- Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.
- Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day).
Exclusion Criteria:
- Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
- History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, particularly GI disease, especially peptic ulceration, clinically significant GI bleeding, UC, CD, Irritable Bowel Syndrome or malabsorption syndrome that may impair bioavailability, and neurological or psychiatric disorder
- Participants who are unable to take oral medication.
- Acute diarrhea, constipation or vomiting in the 7 days before the predicted Day 1. If screening occurs >7 days before Day 1his criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: [14C]OD-001
oral solution |
[14C]OD-001 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Mass balance recovery of total radioactivity in all excreta: CumAe
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Mass balance recovery of total radioactivity in all excreta: Cum%Ae
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Number of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Identity of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood by LC-MS and NMR
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Rate of elimination of [14C]OD-001 in excreta by Ae
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by %Ae
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Secondary Rate of elimination of [14C]OD-001 in excreta by CumAe
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by Cum%Ae by interval
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of treatment-emergent adverse events
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Percentage of [14C] total radioactivity OD-001 metabolites in excreta
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Tmax of OD-001 in blood, total radioactivity in blood and plasma
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Cmax of OD-001 in blood, total radioactivity in blood and plasma
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
AUC0-last of OD-001 in blood, total radioactivity in blood and plasma
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
T1/2 of OD-001 in blood, total radioactivity in blood and plasma
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal clinical laboratory test results
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal electrocardiograms (ECGs)
Periodo de tiempo: Day 1 to Day 8
|
Day 1 to Day 8
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sharan Sidhu, MBChB, BAO, MRCS, MFPM, Quotient Sciences
- Director de estudio: Anthony Opipari, Odyssey Therapeutics, Inc.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- OD-001-100
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .